Zevra Therapeutics, Inc. ZVRA

What this company does

Zevra Therapeutics, Inc. markets its lead product in the United States for the treatment of Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease. As of December 31, 2025, it employed 61 full-time employees. It has built a portfolio of products and product candidates through internal development and strategic investments and acquisitions. The FDA approved MIPLYFFA on September 20, 2024, for use in combination with miglustat for the treatment of neurological manifestations of NPC in patients 2 years of age and older, and MIPLYFFA became commercially available for dispense in the United States in November 2024. OLPRUVA, a sodium phenylbutyrate oral suspension, is approved in the United States as adjunctive therapy to standard of care for the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. AZSTARYS, a partnered product, is marketed in the United States under the company's September 2019 collaboration and license agreement with Commave. It is also advancing celiprolol as an investigational product candidate for the treatment of Vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen (COL3A1) mutation. It was incorporated under the laws of the State of Iowa in October 2006, reincorporated under the laws of the State of Delaware in May 2014, and changed its name from KemPharm, Inc. to Zevra Therapeutics, Inc. effective February 21, 2023.

Written from the business description in Zevra Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.